Abstract

There is provided a polymer composition comprising a multi-block thermogelling polymer comprising a hydrophilic poly(alkylene glycol), a hydrophobic polymer, and a polyether or polyester chemically coupled together by at least one of urethane/carbamate, carbonate, ester, carbamide, an amide, ether, amine, triazole, linkages or combinations thereof; and a tyrosine kinase inhibitor (TKI) intermixed with the multi-block thermogelling polymer.

IPC Classes  ?

• C08G 18/48 - Polyethers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 27/02 - Ophthalmic agents

Abstract

The invention belongs to the field of medicinal chemistry, and particularly relates to a novel Pt(IV) complex, nanoparticles and compositions comprising same, methods and uses 5 thereof for the treatment of cancer. More particularly, the Pt(IV) complex comprises formula (I): wherein R1 and R2 are selected from the group comprising a mitochondria-targeting ligand and a chemosensitizer ligand, wherein R1 and R2 are not both mitochondria-targeting 10 ligands or chemosensitizer ligands, and may be used to treat ovarian cancer, preferably cisplatin-resistant ovarian cancer.

IPC Classes  ?

• C01G 55/00 - Compounds of ruthenium, rhodium, palladium, osmium, iridium, or platinum
• A61K 31/282 - Platinum compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present disclosure relates to a catalytic method of producing methane gas fuel from plastic waste. The method comprises subjecting plastic waste to hydrogenolysis under mild conditions in the presence of a Rh-based catalyst to obtain a methane gas fuel, wherein the mild conditions include heating the plastic waste at a temperature of less than 300oC, under 2x106 Pa of hydrogen pressure, and within 3 hours; and wherein the Rh-based catalyst is rhodium supported on a material selected from carbon, titanium dioxide and lanthanum phosphate.

IPC Classes  ?

• C10G 1/10 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal from rubber or rubber waste
• C10G 47/14 - Inorganic carriers the catalyst containing platinum group metals or compounds thereof
• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
• B01J 21/18 - Carbon
• B01J 27/14 - PhosphorusCompounds thereof

Abstract

The present invention relates to the provision of recombinant adeno-associated virus (rAAV) -based delivery vectors comprising short peptide inserts of at least 5 amino acid length, which show enhanced transduction efficiency in one or more muscle cells, particularly in cardiomyocytes and/or skeletal muscle cells. The rAAV vectors of the present disclosure are suitable for use in the treatment and/or prophylaxis of a cardiac-related and/or muscle-related disease or disorder and/or for use in gene therapy. Also provided are methods of treating cardiac-related and/or muscle-related diseases or disorders.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates, in general terms, to biomarkers for liver disease. Provided herein are gene signatures for non-alcoholic fatty liver disease (NAFLD) and methods of use thereof for diagnosis, classification and monitoring of NAFLD in a subject using extracellular vesicle samples from the subject.

IPC Classes  ?

• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

According to embodiments of the present invention, a parallel scanning confocal microscope is provided. The microscope includes an optical circulator including a first port, a second port and a third port; a light source optically coupled to the first port; an optical arrangement in optical communication with the second port; a focusing lens; and a photodetector optically coupled to the third port. The light source may be configured to emit light towards the optical arrangement along an illumination path. The light may be directed as multiple optical beams towards the focusing lens, which may be configured to focus the beams to confocally and simultaneously illuminate a sample along the illumination path; and to collect light reflected from the sample confocally along a reflection path. The reflected light may be directed towards the photodetector along the reflection path. According to further embodiments, a parallel scanning confocal microscopy method is also provided.

IPC Classes  ?

• G02B 21/06 - Means for illuminating specimen
• G01N 21/64 - FluorescencePhosphorescence

Abstract

There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein A comprises a carbohydrate and/or a derivative thereof; R1 and R2 are each independently a hydrophobic group; R3, R4, R5, and R6 are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7, R9 and R10 are each independently optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R8 is –O–, –S–, or –NRa–, where Ra is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; m is 0 or 1; n ≥ 1; and w ≥ 1.

IPC Classes  ?

• C08G 69/10 - Alpha-amino-carboxylic acids
• C08G 69/16 - Preparatory processes
• C08L 77/04 - Polyamides derived from alpha-amino carboxylic acids
• C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/51 - Nanocapsules
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses

Abstract

x33,f33,f) of ≥ 50 pm/V. There is also provided a method of forming the film, as well as an electromechanical device comprising the electromechanical responsive film.

IPC Classes  ?

• H10N 30/076 - Forming of piezoelectric or electrostrictive parts or bodies on an electrical element or another base by depositing piezoelectric or electrostrictive layers, e.g. aerosol or screen printing by vapour phase deposition
• H10N 30/853 - Ceramic compositions
• C01G 33/00 - Compounds of niobium

Abstract

A high-throughput generic computational framework for rational design of allosteric drug candidates is described here. This present invention discloses identifying allosteric sites/effectors on the bases of protein dynamics and utilising knowledge on the physicochemical properties of known allosteric sites and effectors. By requiring a bare minimum of a 3D structure information of a protein of interest, Allosteric Fingerprints are computed by perturbing residues or segments of the protein and quantifying allosteric signalling. A set of binding patches of interest is identified from analysing Allosteric Fingerprints, and one or more compounds are then identified based on allosteric modulation value and predicted binding free energy, resulting in one or more allosteric site-effector pairs, which provide desirable allosteric modulation of targeted function. Further optimization of site-effector pairs is achieved by simultaneous and mutual adjustments between binding sites and effectors, in respective identification and prioritization steps.

IPC Classes  ?

• G16B 20/30 - Detection of binding sites or motifs
• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
• G16C 20/50 - Molecular design, e.g. of drugs

Abstract

This document describes a dual-mode waveguide antenna for single beam emission in an optical phased array system. In particular, the waveguide antenna which comprises a straight section and a periodic sinusoidal tapered section is designed to produce a single emission angle even when two separate optical signals with differing wavelengths are beamed through it.

IPC Classes  ?

• G02F 1/295 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the position or the direction of light beams, i.e. deflection in an optical waveguide structure
• G01S 7/481 - Constructional features, e.g. arrangements of optical elements
• H01Q 5/00 - Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements

Abstract

Various embodiments may relate to a phase shifter. The phase shifter may include rib waveguide. The rib waveguide may include a base and a stacked arrangement on the base, the stacked arrangement including alternate layers of silicon (Si) and layers of silicon-germanium (SiGe). The phase shifter may also include a first slab waveguide region and a second slab waveguide region. A first region of the rib waveguide, the first region of the rib waveguide including a first region of the base and a first region of the stacked arrangement, may be a doped region having a first type conductivity. A second region of the rib waveguide adjoining the first region of the rib waveguide, the second region of the rib waveguide including a second region of the base and a second region of the stacked arrangement, may be a doped region having a second type conductivity.

IPC Classes  ?

• G02B 6/122 - Basic optical elements, e.g. light-guiding paths
• G02F 1/025 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on semiconductor elements having potential barriers, e.g. having a PN or PIN junction in an optical waveguide structure
• G02B 6/13 - Integrated optical circuits characterised by the manufacturing method
• G02F 1/225 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference in an optical waveguide structure

Abstract

There is provided an engineered mitochondrion comprising one or more exogenous protein binding motif/peptide expressed on the outer membrane of the mitochondrion. Also disclosed is a polynucleotide, a vector, a host cell, a cell, a composition or pharmaceutical composition, and a method of treatment thereof. Also disclosed is a method of improving mitochondrion uptake into a target cell comprising genetically modifying a host cell to express a modified mitochondrion, wherein the modified mitochondrion comprises one or more exogenous protein binding motif/peptide expressed on the outer membrane of the mitochondrion.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

A decoder for decoding a codeword of a Tunstall code is provided, including: a sub-decoder configured to receive an input codeword of the Tunstall code to the decoder and output a decoded symbol of the input codeword: a symbol memory configured to receive and store the decoded symbol of the input codeword from the sub-decoder; and a controller configured to control the symbol memory to output one or more decoded symbols stored in the symbol memory. The sub-decoder includes: a node memory configured to store, for a plurality of nodes of a Tunstall tree of the Tunstall code corresponding to a first level of the Tunstall tree, a plurality of codewords of the Tunstall code assigned to the plurality of nodes, respectively: and a comparator configured to compare the input codeword with the plurality of codewords assigned to the plurality of nodes corresponding to the first level of the Tunstall tree received from the node memory and produce the decoded symbol of the input codeword with respect to the first level of the Tunstall tree based on the comparison. Another decoder for decoding a codeword of a Tunstall code is also provided, including: a symbol memory comprising a plurality of memory entries, each memory entry having stored therein one or more decoded symbols of a codeword of the Tunstall code corresponding to the memory entry; and a controller configured to receive an input codeword of the Tunstall code to the decoder and control the symbol memory to output the one or more decoded symbols stored in one of the plurality of memory entries corresponding to the input codeword.

IPC Classes  ?

• H03M 7/30 - CompressionExpansionSuppression of unnecessary data, e.g. redundancy reduction
• H03M 7/40 - Conversion to or from variable length codes, e.g. Shannon-Fano code, Huffman code, Morse code

Abstract

This disclosure concerns spirocyclo terpene compounds and their biosynthesis thereof. In particular, the terpene compound has a spiro-tricyclic scaffold. The biosynthetic method comprises fermenting a cellular organism having a sesquiterpene synthetase enzyme, wherein the STS enzyme is characterised by SEQ 7 and/or SEQ 11.

IPC Classes  ?

• C07C 13/72 - Spiro hydrocarbons
• C12P 15/00 - Preparation of compounds containing at least three condensed carbocyclic rings

Abstract

The present disclosure concerns compositions comprising a compound of Formula (I) or a salt, solvate or stereoisomer thereof, wherein the compound of Formula (I) is characterised by a concentration of at least 80 ppm relative to the composition. The present disclosure also concerns methods of formulating the compositions. The present disclosure also concerns methods of providing an aroma to a composition.

IPC Classes  ?

• C11B 9/00 - Essential oilsPerfumes
• C07C 13/72 - Spiro hydrocarbons
• A61K 8/31 - Hydrocarbons
• A61Q 13/00 - Formulations or additives for perfume preparations

Abstract

Herein disclosed is a water-soluble ceramic core that includes a metal oxide including an alkaline earth metal, a carbon material including graphite, a reinforcement agent, and a binder. A method for forming the ceramic core, and an investment casting method, are also disclosed.

IPC Classes  ?

• B22C 1/02 - Compositions of refractory mould or core materialsGrain structures thereofChemical or physical features in the formation or manufacture of moulds characterised by additives for special purposes, e.g. indicators, breakdown additives
• B22C 9/10 - CoresManufacture or installation of cores
• C04B 35/04 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on magnesium oxide, calcium oxide or oxide mixtures derived from dolomite based on magnesium oxide
• C04B 35/622 - Forming processesProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products

Abstract

This document describes a multiplexer for very high frequency applications. The multiplexer comprises two or more arms whereby each arm of the multiplexer comprises a bandpass filter that is implemented using a multi-stage LC ladder circuit that connects an input terminal to a first output terminal, and a capacitor connected in series between a series inductor and a parallel capacitor of a final stage of the first multi-stage LC ladder circuit on a path connecting the input terminal and the first output terminal. The capacitor connected in series at the final stage of the first multi-stage LC ladder circuit has a resonant frequency located within the passband of the bandpass filter.

IPC Classes  ?

• H03H 7/46 - Networks for connecting several sources or loads, working on different frequencies or frequency bands, to a common load or source
• H03H 7/075 - Ladder networks, e.g. electric wave filters

Abstract

There is provided a genetically modified cell wherein at least one gene has been deleted from the cell and the gene is selected from the group consisting of p50, p52, p65, c-Rel, and RelB. Also disclosed are methods of identifying a target for treating acute myeloid leukemia (AML) in a subject, methods of treating acute myeloid leukemia (AML) in a subject in need thereof, comprising inhibiting the activity of an NF-KB pathway. Also provided is an ATP13A2 inhibiting agent for use in therapy or medicine, for use in treating AML, and in the manufacture of a medicament for treating AML.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C12N 5/0789 - Stem cellsMultipotent progenitor cells

Abstract

The present invention relates to modified U1 snRNAs configured to rescue exon skipping in a mutated ABCA4 gene. In one aspect of the present invention, there is provided a modified U1 small nuclear RNA (snRNA) configured to retain exon 40 in a mature mRNA transcript of a mutated ABCA4 gene, the mutated ABCA4 gene comprising a mutation that induces skipping of exon 40, wherein the mutation is located between 3 base pairs upstream and 8 base pairs downstream of a donor splice site of exon 40, wherein the modification comprises replacing a portion of a single-stranded nucleotide sequence of a 5' region of a wild-type U1 snRNA with a single-stranded binding nucleotide sequence capable of hybridizing to a target sequence present on a pre-mRNA transcript of the mutated ABCA4 gene, and wherein the target sequence is located in a region between 13 base pairs upstream and 15 base pairs downstream of the donor splice site of exon 40. In another aspect, there is provided a nucleic acid construct comprising a polynucleotide sequence encoding the modified U1 snRNA as described herein.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/00 - Drugs for disorders of the senses

Abstract

In some embodiments, a hyperspectral imaging system is provided. The system includes a first optical assembly configured to receive light and disperse the light into multiple channels, and a second optical assembly configured to receive the light dispersed by the first assembly, and image each of the multiple channels of the light onto a focal plane array of a detector. At least one of the first optical assembly and the second optical assembly include a flat optic.

IPC Classes  ?

• G01J 3/18 - Generating the spectrumMonochromators using diffraction elements, e.g. grating
• G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements
• G01J 3/28 - Investigating the spectrum
• G02B 5/18 - Diffracting gratings
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals

Abstract

An Advanced Encryption Standard (AES) cryptographic system and a method of performing Advanced Encryption Standard (AES) cryptography. The method comprises the steps of performing multiplicative inversion for SubBytes transformation using two forward-reverse linear-feedback shift registers, LFSRs, pairs; and using different respective initialization seeds for the pairs of forward-reverse LFSRs.

IPC Classes  ?

• H04L 9/06 - Arrangements for secret or secure communicationsNetwork security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems

Abstract

Disclosed are p53 peptidomimetic macrocycles, each p53 peptidomimetic macrocycle comprising an i, i+4 olefin staple and a polypeptide tail covalently linked to the p53 peptidomimetic macrocycle; an i, i+7 olefin staple and a polypeptide tail covalently linked to the p53 peptidomimetic macrocycle; or, an i, i+7 di-alkyne staple and optionally a polypeptide tail covalently linked to the p53 peptidomimetic macrocycle; wherein the p53 peptidomimetic macrocycle comprises all D-configuration amino acids and the polypeptide tail comprises three to nine amino acids, each amino acid of the polypeptide tail independently having a D-configuration or an L-configuration. The p53 peptidomimetic macrocycles are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX, thereby antagonizing MDM2 and MDMX binding to p53. These p53 peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 31/203 - Retinoic acids
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 33/243 - PlatinumCompounds thereof
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/12 - Cyclic peptides
• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Various embodiments may relate to a photodiode. The photodiode may include a first germanium-containing region. The photodiode may include also a second germanium- containing region. The photodiode may further include a barrier between the first germanium- containing region and the second germanium-containing region. The photodiode may additionally include a first doped region in contact with the first germanium-containing region, the first doped region being of a first electrical conductivity type. The photodiode may also include a second doped region in contact with the second germanium-containing region, the second doped region being of a second electrical conductivity type different from the first electrical conductivity type.

IPC Classes  ?

• H10F 30/223 - Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors the devices having potential barriers, e.g. phototransistors the devices being sensitive to infrared, visible or ultraviolet radiation the devices having only one potential barrier, e.g. photodiodes the potential barrier being a PIN barrier
• H10F 77/10 - Semiconductor bodies

Abstract

An object detection network training method includes receiving images showing an object and comprising a ground truth bounding box, and ground truth mask, for the object. Image features are extracted and bounding boxes are predicted for the object. A combined loss is calculated for the bounding boxes, comprising a bounding box regression loss between the one or more predicted bounding boxes and the ground truth bounding box for the object in the image, and an instance coverage loss of the one or more predicted bounding boxes relative to ground truth mask. A bounding box regression network is updated using the combined loss, and the process repeats until convergence. The object detection network can then determine a final bounding box based on the boxes predicted by the trained regression network.

IPC Classes  ?

• G06N 3/02 - Neural networks
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06T 7/00 - Image analysis

Abstract

The invention relates to an endovascular stent comprising a tubular expandable lattice structure comprising a plurality of negative Poisson' s ratio (NPR) cells in connection with at least one row of positive Poisson's ratio (PPR) cells provided along a length of the stent. Each NPR cell may have a shape of a re-entrant (RE) hexagon. The stent may be automatically bent after expansion. The invention also relates to an endovascular stent graft comprising the endovascular stent and a liner provided around the endovascular stent.

IPC Classes  ?

• A61F 2/07 - Stent-grafts

Abstract

The crosslinked peptidomimetic macrocycles disclosed herein comprise an alkene or alkyne staple and a poly-amino acid C-terminal tail. These crosslinked peptidomimetic macrocycles have improved binding to MDM2 and MDMX (aka MDM4), are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX thereby antagonizing MDM2 and MDMX binding to p53. These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.

IPC Classes  ?

• C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

An improved nanocomposite There is provided a nanocomposite comprising a carbon nanodot (C-dot) and an enzyme, co-encapsulated in a metal-organic framework. There is also provided a method of forming the same.

IPC Classes  ?

• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• C01B 32/15 - Nanosized carbon materials

Abstract

An acoustic transducer that may include a substrate including a cavity extending from a surface of the substrate, where the substrate further includes one or more acoustic channels, each of the one or more acoustic channels having a depth extending from the surface of the substrate and a length, the length greater than the depth, extending at least partially around the cavity. The acoustic transducer may also include a layered arrangement suspended over the cavity. The one or more acoustic channels may be configured to include an acoustic medium having a specific acoustic impedance lower than a specific acoustic impedance of the substrate.

IPC Classes  ?

• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for

Abstract

According to embodiments of the present invention, a sweat sensing device is provided. The sweat sensing device includes a continuous piece of hydrophilic paper including a first region for receiving sweat, a second region opposite the first region, and a third region therebetween; a flexible hydrophobic film having an opening; and a sensor unit. The hydrophobic film and the hydrophilic paper are arranged adjacent to each other with the opening aligned to and exposing the second region. The sensor unit is configured to facilitate a measurement based on the diffused sweat. The hydrophobic film and the hydrophilic paper are collectively folded in a stacked manner such that the sensor unit is sandwiched between the third and second regions. The hydrophilic paper is adapted for the received sweat to diffuse laterally along the hydrophilic paper. According to further embodiments, a method for forming the sweat sensing device is also provided.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Method and system for detecting a lane are provided herein. In an embodiment, the method comprises: receiving one or more source detecting images captured by an image capturing device (102) at step S302, the or each of the source detecting images including a source road region having lane features; generating a translated source image corresponding to each of the one or more source detecting images by using a lane feature enhancement module (122) at step S304, with the lane features of the source road region being enhanced in the translated source image; and detecting the lane from the translated source image at S306; wherein the lane feature enhancement module (122) is trained by a plurality of training images and comprises a generator network, to: identify a road region (136) of a corresponding training image of the plurality of training images, translate the road region (136) of the corresponding training image to a translated road region to minimize a loss function that quantifies a dissimilarity between the road region (136) and the translated

IPC Classes  ?

• G06V 20/56 - Context or environment of the image exterior to a vehicle by using sensors mounted on the vehicle
• G06T 5/60 - Image enhancement or restoration using machine learning, e.g. neural networks

Abstract

Embodiments of the invention provide for a multimodal microscopy system. The multimodal microscopy system may include an illumination module configured to provide a light beam to a sample under test via a delivery path; and an optical arrangement configured to receive the light beam from the sample through a detection path to generate a microscopy image of the sample. The optical arrangement may be operable to switch among a plurality of imaging modalities using the detection path shared by the plurality of imaging modalities. The plurality of imaging modalities may include brightfield microscopy, fluorescent microscopy, and endoscopic microscopy. The multimodal microscopy system may be a multimodal hyperspectral microscopy system.

IPC Classes  ?

• G02B 21/12 - Condensers affording bright-field illumination
• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
• A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
• G01N 21/64 - FluorescencePhosphorescence
• G02B 21/16 - Microscopes adapted for ultraviolet illumination
• G02B 21/26 - StagesAdjusting means therefor
• G02B 21/36 - Microscopes arranged for photographic purposes or projection purposes
• G02B 27/14 - Beam splitting or combining systems operating by reflection only
• G02B 27/30 - Collimators

Abstract

There is provided a brazzein variant comprising a circular permutation brazzein. Also disclosed are polynucleotides, vector, host cells, and methods of producing the brazzein variant. Also disclosed are methods of increasing the sweetness of a food product and a method of producing a food product comprising the brazzein as disclosed herein.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• A23L 27/30 - Artificial sweetening agents
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin

Abstract

Spray-dried Compositions and Methods of Preparation Spray-dried compositions that may be used in food products, the methods of preparing the compositions and food products containing the compositions are described. The spray-dried composition contains 5 to 50 weight percent (wt. %) of a prebiotic. 10 to 65 wt. % of a probiotic, and 30 to 80 wt. % of a coating material. The prebiotic may be a polysaccharide, an oligosaccharide, a polyol, whey protein, and any combinations thereof. The probiotic may be Lacticaseibacillus, Lactobacillus, Lactiplantibacillus, Levilactobacillus, Ligilactobacillus, Limosilactobacillus, Bifidobacterium, Enterococcus, Streptococcus, Pediococcus, Leuconostoc, Bacillus, Escherichia, Saccharomyces, and any combinations thereof. The coating material may be a synthetic polymer, a natural polymer, and any combinations thereof. The spray-dried compositions are prepared by providing at least one solution containing the composition components and spray drying the at least one solution.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23C 9/16 - Agglomerating or granulating milk powderMaking instant milk powderProducts obtained thereby
• A23G 9/36 - Frozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition containing microorganisms or enzymesFrozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition containing paramedical or dietetical agents, e.g. vitamins
• A61K 9/50 - Microcapsules
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/745 - Bifidobacteria
• C12C 5/00 - Other raw materials for the preparation of beer

Abstract

A beamforming transmission system and a method of controlling an output power of a beamforming transmission system are disclosed, the system comprising one or more transmission elements, the one or more transmission elements each comprising a power amplifier; an antenna coupled to the power amplifier; and a power detector coupled to the antenna; a power controller coupled to the power amplifier; a system processing module coupled to the one or more transmission elements, the system processing module further coupled to the power controller, the system processing module being arranged to instruct the power controller to control an output power of the power amplifier; wherein the system processing module is arranged to determine a desired beam scanning angle of the one or more transmission elements and to obtain a present output power of the power amplifier from the power detector; and further wherein the system processing module is arranged to instruct the power controller to control the output power of the power amplifier based on both the desired beam scanning angle and the present output power of the power amplifier.

IPC Classes  ?

• H01Q 3/28 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the relative phase or relative amplitude of energisation between two or more active radiating elementsArrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture varying the amplitude
• H03F 3/24 - Power amplifiers, e.g. Class B amplifiers, Class C amplifiers of transmitter output stages

Abstract

This technology relates to the production of lactose and human milk oligosaccharides (HMOs) in cells.

IPC Classes  ?

• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C07K 14/76 - Albumins
• C12N 9/10 - Transferases (2.)
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12P 19/12 - Disaccharides

Abstract

Antibodies and antigen-binding fragments thereof specific to Trophoblast cell surface antigen 2 (Trop2). Also provided are anti-Trop2 antibody-drug conjugates (ADCs), Trop2-specific chimeric antigen receptor, and multispecific antigen binding proteins, such as bispecific T cell engagers (BiTEs), which bind to Trop2 and other targets. Further provided are compositions comprising the anti-Trop2 antibodies and antigen-binding fragments thereof, a method of diagnosis and cancer treatment employing the anti-Trop2 antibodies and antigen-binding fragments thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/725 - T-cell receptors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

According to embodiments of the present invention, an optical arrangement is provided. The optical arrangement includes a first fiber optic probe configured to measure Raman spectra of a skin sample; a second fiber optic probe configured to measure diffuse reflectance spectra of the skin sample; and an imaging camera configured to capture a reflectance image of the skin sample. The first fiber optic probe, at least part of the second fiber optic probe and the imaging camera are arranged adjacent to one another. Based on at least one selected from the measured Raman spectra, the measured diffuse reflectance spectra, or the captured reflectance image, the optical arrangement is configured to interrogate a pre-determined depth below a surface of the skin sample, and/or tissue chromophores of the skin sample at the pre-determined depth. According to further embodiments, a device and non-invasive method for analyzing a skin sample are also provided.

IPC Classes  ?

• A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01N 21/65 - Raman scattering

Abstract

Systems and methods for quantifying circulating tumour DNA (ctDNA) in a plasma sample by performing fragment length analysis of the sequencing data using a ctDNA quantification model to estimate a ctDNA metric of the blood plasma sample. Wherein the ctDNA quantification model comprises a neural network based system trained using a training dataset generated using control cfDNA data augmented with ctDNA data obtained from known cancer samples to generate artificial training dataset records with a known ctDNA metric.

IPC Classes  ?

• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 40/20 - Supervised data analysis

Abstract

A computer system for analysing liquid chromatography electrospray ionisation mass spectrometry (LC-ESI-MS) data. The computer system is configured to implement a raw data processor that extracts a mass spectrum based on data at each retention time and a base peak signal intensity derived from the peak apex and the baseline, from a base peak chromatogram derived from raw LC- ESI-MS data. The system also implements a fingerprinting system performing background correction for detected peaks, producing a m/z value by subtracting mass over charge (m/z) values of the baseline from an original m/z value and, if the resulting m/z value is positive, restoring the original m/z value. The fingerprinting system generates a compact data representation comprising, for each detected peak, the retention time, original m/z values and intensities, and performs chemical fingerprinting for the raw LC-ESI-MS data based on the compact data representation.

IPC Classes  ?

• G01N 30/72 - Mass spectrometers
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G06F 17/10 - Complex mathematical operations
• G06F 16/20 - Information retrievalDatabase structures thereforFile system structures therefor of structured data, e.g. relational data
• G06F 16/24 - Querying

Abstract

There is provided a system and a method of non-contact measurement of one or more mechanical properties of a material, the system comprising an ultrasonic module comprising an ultrasonic applicator configured to apply ultrasonic pressure on a target region of the material; a detection module comprising an electromagnetic wave emitter and an electromagnetic wave detector, said electromagnetic wave emitter being configured to emit an incident beam of electromagnetic waves towards the target region of the material, and said electromagnetic wave detector being configured to detect an emergent beam of electromagnetic waves reflected from the target region and/or transmitted through the target region; and a processing module configured to determine one or more measures corresponding to the one or more mechanical properties of the material, based on changes in the emergent beam of electromagnetic waves.

IPC Classes  ?

• G01N 29/24 - Probes
• A61B 8/10 - Eye inspection
• G01N 29/04 - Analysing solids
• G01N 29/07 - Analysing solids by measuring propagation velocity or propagation time of acoustic waves
• G01N 33/483 - Physical analysis of biological material

Abstract

The present disclosure relates to a catalytic method of producing sustainable aviation fuel from plastic waste. The method comprises subjecting plastic waste to hydrocracking under mild conditions in the presence of a catalyst to obtain a sustainable aviation fuel, wherein the mild conditions include heating the plastic waste at a temperature of less than 300oC, under 2x106 Pa of hydrogen pressure, and within 3 hours; and wherein the catalyst is a bimetallic Rh-based catalyst, Rh2MoOx, supported on an Al-SBA-15 material, represented by Rh2MoOx/Al-SBA- 15.

IPC Classes  ?

• C10G 1/10 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal from rubber or rubber waste
• B01J 29/74 - Noble metals
• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• C10G 47/18 - Crystalline alumino-silicate carriers the catalyst containing platinum group metals or compounds thereof

Abstract

An electromechanical responsive film There is provided an electromechanical responsive film comprising aluminium scandium nitride having formula Al1-xScxN1-2y/3Oy, wherein 0.45 ≤ x ≤ 0.6 and 0 ≤ y ≤ 0.15. There is also provided an electromechanical responsive device comprising the electromechanical responsive film.

IPC Classes  ?

• H10N 30/853 - Ceramic compositions
• H10N 30/093 - Forming inorganic materials
• H10N 30/076 - Forming of piezoelectric or electrostrictive parts or bodies on an electrical element or another base by depositing piezoelectric or electrostrictive layers, e.g. aerosol or screen printing by vapour phase deposition

Abstract

Disclosed herein is a cortisol sensor, comprising or consisting of: i) a metal nanoparticle; ii) a plurality of cortisol binding ligands conjugated to the surface of the metal nanoparticle; and iii) a plurality of peptides conjugated to the surface of the metal nanoparticle, for reducing non-specific binding of the cortisol binding ligands and/or improving stability of the metal nanoparticle in solution. In particular, the metal nanoparticle is a gold nanoparticle, the cortisol binding ligand is a cortisol DNA aptamer, and the peptide is CALNN. Also disclosed is a method of detecting the presence or quantity of cortisol in a sample, comprising or consisting the steps of: a) providing the cortisol sensor; b) contacting the cortisol sensor to the sample in a saline environment; and c) determining the degree of aggregation of the cortisol sensor. In particular, the degree of aggregation is measured by UV-visible spectroscopy.

IPC Classes  ?

• G01N 33/553 - Metal or metal coated
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

Abstract

A microfluidic chip (12) for sample preparation and a sample preparation system (10) are provided. The microfluidic chip (10) includes: a chip body (14) and a plurality of injection ports (16, 18, 24, 30, 36, 38, 40) provided in the chip body (14). A plurality of chambers (20, 26, 32) and a plurality of mixers (22, 28, 34) are provided in the chip body (14). A first chamber (20) is configured to receive a sample via a first injection port (16) and a reducing agent via a second injection port (18). A first mixer (22) in fluid communication with the first chamber (20) is operable to mix the sample and the reducing agent from the first chamber (20) to produce a denatured and reduced sample. A second chamber (26) in fluid communication with the first mixer (22) is configured to receive an alkylating agent via a third injection port (24). A second mixer (28) in fluid communication with the second chamber (26) is operable to mix the denatured and reduced sample with the alkylating agent to produce an alkylated sample. A third chamber (32) in fluid communication with the second mixer (28) is configured to receive a protein precipitation solution via a fourth injection port (30). A third mixer (34) in fluid communication with the third chamber (32) is operable to mix the alkylated sample with the protein precipitation solution to produce a precipitated sample. A reaction chamber (42) in fluid communication with the third mixer (34) is provided in the chip body (14), the reaction chamber (42) being configured to receive a washing buffer via a fifth injection port (36), a digestion buffer via a sixth injection port (38) and an elution buffer via a seventh injection port (40). A depth filter (43) is received in the reaction chamber (42). A first discharge port (44) and a second discharge port (46) are provided in the chip body (14) in fluid communication with the reaction chamber (42). The first discharge port (44) is operable to discharge waste from the reaction chamber (42) and the second discharge port (46) is operable to discharge a prepared sample.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

Disclosed are optical detection device, system, and method which increase photodetection area and enables omnidirectional and self-aligning photodetection through the use of a fluorescent lens. An optical detection device comprises a fluorescent lens having a light collecting area being a spherical, hemispherical, or cylindrical surface of the fluorescent lens, and a light outcoupling area; and a fluorophore dispersed throughout the light collection area and the fluorescent lens, wherein the fluorophore is excitable by a light beam, which is incident at any position or angle in relation to the spherical surface, to produce a light emission, wherein the light outcoupling area is arranged to allow an extraction of the light emission from the fluorescent lens, wherein the light collecting area is larger than the light outcoupling area.

IPC Classes  ?

• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• G01J 3/12 - Generating the spectrumMonochromators
• G01J 3/42 - Absorption spectrometryDouble-beam spectrometryFlicker spectrometryReflection spectrometry
• G01J 3/433 - Modulation spectrometryDerivative spectrometry
• G01J 3/44 - Raman spectrometryScattering spectrometry

Abstract

A flame retardant synergist including a repeating unit including a backbone represented by a formula of: A flame retardant synergist including a repeating unit including a backbone represented by a formula of: A flame retardant synergist including a repeating unit including a backbone represented by a formula of: where moiety A is derived from a substituted triazine having at least two amino groups, and where moiety B is derived from a dialdehyde having a terminal aldehyde. Furthermore, moiety A and moiety B are bonded via a —C—N— linkage formed from having one of the at least two amino groups reacted with the terminal aldehyde, where n ranges from 5 to 1000. Additionally, one or more side units extend from the backbone, where the one or more side units are derived from 9,10-dihydro-9-oxa-10-phosphaphenanthrene 10-oxide or a derivative thereof. Furthermore, a flame retardant polymer composite that includes a polymer, the flame retardant synergist, and a flame retardant additive, is disclosed herein. Methods of forming the flame retardant synergist and the flame retardant polymer composite are further disclosed herein.

IPC Classes  ?

• C09K 21/14 - Macromolecular materials
• C08G 12/34 - Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with heterocyclic compounds and acyclic or carbocyclic compounds
• C08G 12/40 - Chemically modified polycondensates
• C08L 77/02 - Polyamides derived from omega-amino carboxylic acids or from lactams thereof

Abstract

Various embodiments may relate to a method of forming a photoresist. The method may include forming the photoresist by mixing a sol-gel acrylic polymer-nanoparticles resin with a nanoparticles-dispersed acrylic resin. The sol-gel acrylic polymer-nanoparticles resin may be formed by mixing a monomer, a nanoparticle precursor, a coupling agent, a crosslinker and a photoinitiator in a sol-gel process. Each nanoparticle of a plurality of nanoparticles included in the photoresist may have a diameter selected from a range from 10 nm to 20 nm such that the photoresist is ultra-violet curable.

IPC Classes  ?

• G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
• G03F 7/004 - Photosensitive materials
• C08L 33/12 - Homopolymers or copolymers of methyl methacrylate
• C08L 33/16 - Homopolymers or copolymers of esters containing halogen atoms
• C08K 3/22 - OxidesHydroxides of metals

Abstract

Disclosed is a system for respiratory system secretion management. The system comprises an oscillatory wave generator for generating a wave for loosening secretion from a respiratory system of a subject, a nasal module in communication with the oscillatory wave generator, for delivering the wave through a nasal passage of the subject, a power module configured to power the system, and a communication module coupled to at least one of the nasal module and the oscillatory wave generator. The communication module is for selectively communicating power and/or one or more waveform characteristics to the respective nasal module and/or oscillatory wave generator.

IPC Classes  ?

• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
• A61M 16/06 - Respiratory or anaesthetic masks

Abstract

There is provided a nanoparticle composition comprising a compound represented by general formula (1) or ionized form thereof, wherein R1, R2, and R4to R8are each independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, R3is optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene, and R9and R10are each independently a hydrophobic tail or contains at least one of the groups defined above for R4to R8; a therapeutic, prophylactic, and/or biological agent that is encapsulated by the compound of general formula (1) to form nanoparticles; and a cryoprotectant. There is also provided a method of preparing said nanoparticle composition.

IPC Classes  ?

• C07C 233/36 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
• A61K 9/133 - Unilamellar vesicles
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/04 - Antibacterial agents
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein is a method of modifying T cells during T cell activation, comprising contacting the T cells with an inhibitory agent for prolyl hydroxylase. Also disclosed is a method of producing Chimeric Antigen Receptor (CAR) or T cell Receptor (TCR) T cells, comprising (i) modifying T cells during T cell activation by contacting the T cells with an inhibitory agent for prolyl hydroxylase, (ii) introducing a CAR or TCR transgene into the modified T cells, and (iii) harvesting the CAR or TCR T cells. In particular, the inhibitory agent for prolyl hydroxylase is a small molecule prolyl hydroxylase inhibitor, such as 1,4-DPCA. The harvested CAR or TCR T cells may be used for adoptive T cell immunotherapy of cancer.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

There is provided a modified cell expressing (a) a chimeric antigen receptor targeting GPC3 and/or CD19, and (b) a multi-specific antigen binding protein, variant or binding fragment thereof that binds one or more target, comprising a first antigen binding protein, variant or binding fragment thereof that binds to EpCAM (epithelial cell adhesion molecule) and a second antigen binding protein, variant or binding fragment thereof that binds to an immune cell marker, wherein the first antigen binding protein, variant or binding fragment thereof that binds to EpCAM comprises a heavy chain variable region and/or a light chain variable region comprise sequences as disclosed herein. Also disclosed are methods of producing/generating the cell as disclosed herein and methods of treatment employing the cell as disclosed herein.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 25/17 -
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to antigen binding proteins, variants and fragments thereof specific to Epithelial Cellular Adhesion Molecule (EpCAM) and multispecific antigen binding proteins, such as bispecific T cell engagers (BiTEs), which bind to EpCAM and also other targets. Also provided are compositions comprising the antigen binding proteins, variants and fragments thereof, a cell expressing/secreting the same, a method of treatment employing the antigen binding proteins, variants and fragments thereof, and other uses thereof. In an embodiment, the cell is an Immune cell, for example selected from the group comprising a T cell, a macrophage, a monocyte, and an NK cell. In a more specific embodiment, the cell is a CAR T-cell.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/725 - T-cell receptors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61P 35/00 - Antineoplastic agents

Abstract

There is provided a modified cell expressing (a) a chimeric antigen receptor targeting HER2, and (b) a multi-specific antigen binding protein, variant or binding fragment thereof that binds one or more target, comprising a first antigen binding protein, variant or binding fragment thereof that binds to EpCAM (epithelial cell adhesion molecule) and a second antigen binding protein, variant or binding fragment thereof that binds to an immune cell marker, wherein the first antigen binding protein, variant or binding fragment thereof that binds to EpCAM comprises a heavy chain variable region and/or a light chain variable region comprise sequences as disclosed herein. Also disclosed are methods of producing/generating the cell as disclosed herein and methods of treatment employing the cell as disclosed herein.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C07K 14/275 - Hafnia (G)
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

Various embodiments may relate to a method of forming a coated glass microsphere. The method may include providing a titanium precursor to a glass microsphere in presence of water to form the coated glass microsphere via partial hydrolysis of the titanium precursor. The coated microsphere may include a plurality of titania rods, the plurality of titania rods being amorphous, on a surface of the glass microsphere.

IPC Classes  ?

• C03C 17/25 - Oxides by deposition from the liquid phase
• C09D 5/32 - Radiation-absorbing paints
• C09D 5/33 - Radiation-reflecting paints
• C09D 7/62 - Additives non-macromolecular inorganic modified by treatment with other compounds
• B01J 13/02 - Making microcapsules or microballoons

Abstract

Method and apparatus for multi-label text classification, the method comprising: receiving text input; splitting the text input into one or more sentences; process the one or more sentences to obtain one or more text chunks using one or more grammar models; inputting one or more text chunks to a multi-label text classification model comprising a supervised learning model for text classification and a pre-trained language model to predict labels for the one or more text chunks; comparing probabilities of the predicted labels to obtain one or more predicted labels having predefined probability values.

IPC Classes  ?

• G06N 20/20 - Ensemble learning
• G06F 16/35 - ClusteringClassification
• G06F 40/284 - Lexical analysis, e.g. tokenisation or collocates
• G06F 40/279 - Recognition of textual entities
• G06F 40/30 - Semantic analysis

Abstract

There is provided a method of regenerating a liver cell in a subject having a liver cell degeneration, comprising administering an agent that modulates one or more gene or marker comprising C1ORF131 (2810004N23Rik), SLC45A4, NFKBIB, ARL6IP5, DBNL, GOLGA7B, FAM117B, MED28, TSC22D4, EIF4EBP1, PFN1, PNRC2, ZNF672 (Zfp672), IER5, ADAMTSL5, COL4A5, MYH15, and ILKAP, wherein the agent counteracts the liver cell degeneration and/or enhances a liver cell regeneration. Also disclosed are nucleic acid encoding an agent for inhibiting the one or more gene or marker, composition or a vector or a plasmid comprising the nucleic acids, a kit comprising the nucleic acids, and a composition or vector or plasmid for use in therapy.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a composition comprising a self-assembled nanocomplex, wherein the self-assembled nanocomplex comprises one or more active agent physically bound to one or more conjugate, wherein each conjugate comprises one or more flavonoid molecule and a first water-soluble polymer, and the nanocomplex is at least partially encapsulated by a second water-soluble polymer. The present invention also relates to a method of preparing the composition and uses thereof. The present invention also relates to a method of treating an eye disease caused by angiogenesis, comprising administering a composition to a subject in need thereof, wherein the composition comprises a self-assembled nanocomplex, wherein the self-assembled nanocomplex comprises an ophthalmic anti-angiogenesis drug physically bound to one or more conjugate, each conjugate comprising one or more flavonoid molecule and a first water-soluble polymer.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 27/02 - Ophthalmic agents

Abstract

The present disclosure concerns a compound of Formula (I) or a salt, solvate, stereoisomer or prodrug thereof as a 3CLpro inhibitors. The compounds may be used for treating a coronavirus related disease or condition. (I)

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 487/14 - Ortho-condensed systems
• C07D 471/04 - Ortho-condensed systems
• C07D 471/14 - Ortho-condensed systems
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 31/14 - Antivirals for RNA viruses

Abstract

This technology relates to anti-bacterial peptides and a method of treating infections using the peptides.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 31/04 - Antibacterial agents

Abstract

There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein A comprises a hydrophilic moiety selected from carbohydrate/sugar/saccharide and derivatives thereof; X1is –ORaor –NRbRc; X4is –ORy, –SRzor a hydrophilic group, where Ryto Rzare independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; X2and X3are each independently –O– or –NRd–, where Rato Rdare independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R1and R2are each independently a hydrophobic group; R3, R4, R5, R6, R8and R10are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7, R9, R11and R12are each independently optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R13is H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, or –C(=O)R14, where R14 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl; w ≥ 1; x is 0 or ≥ 1; y is 0 or ≥ 1; and z is 0 or ≥ 1.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 31/785 - Polymers containing nitrogen
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 31/14 - Antivirals for RNA viruses
• C08G 69/08 - Polyamides derived from amino carboxylic acids or from polyamines and polycarboxylic acids derived from amino carboxylic acids
• C08G 69/48 - Polymers modified by chemical after-treatment

Abstract

There is provided an anti-angiogenic agent comprising: a multi-block copolymer in the form of one or more micelles, wherein the copolymer comprises a first poly (alkylene glycol) block, a second poly (alkylene glycol) block and a polyester block. There is also provided a method of preparing said anti-angiogenic agent and medical uses of said anti-angiogenic agent.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 27/02 - Ophthalmic agents
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

There is provided a multi-specific polypeptide construct comprising: (a) one or more antigen targeting domains binding to one or more cancer-associated antigens; and (b) one or more NK cell-targeting domains, wherein binding to NK cells may stimulate and/or suppress innate immune cell functions. Also disclosed are an antigen binding protein, or an antigen-binding fragment thereof; a nucleic acid sequence; a vector; a host cell; a method of producing the multi-specific polypeptide construct, or the antibody; a method of screening and/or identifying the multi-specific polypeptide construct, or the antibody as disclosed herein; a pharmaceutical composition; and a method for treating cancer. In a specific embodiment, the NK cell-targeting domain can bind to Nkp80 and/or CD16 and the cancer-associated antigen can be HER2 and/or EGFR.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

There is provided a method of evaluating risk of severe outcome of an infectious disease and/or an inflammatory disease in a patient, the method comprising: determining/measuring the number of one or more immune cells selected from the group consisting of VD2 T cells, CD8 T cells, and immature neutrophils in a sample obtained from the patient, wherein the patient has an enhanced risk of severe infectious disease and/or inflammatory disease outcome when: (i) the ratio of immature neutrophils to VD2 T cell is at least 2:1, and/or (ii) the ratio of immature neutrophils to CD8 T cell is at least 0.5:1. Also disclosed are method of treating a patient with a severe infectious disease and/or inflammatory disease and kit for use in methods thereof.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 49/00 - Preparations for testing in vivo
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Disclosed is a method of reprogramming somatic cells into induced pluripotent stem cells (iPSCs). Also disclosed is a method of producing, selecting, expanding, characterizing, and differentiating iPSCs. Further disclosed is a method of reprogramming somatic cells selected from the group consisting of fibroblasts IMR90, fibroblasts HFF-01, PBMC, CD3+ T cells and CD34+ hematopoietic stem cells (HSCs) into iPSCs.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• C12N 15/86 - Viral vectors

Abstract

A biocompatible SERS-active polymer membrane configured to detect biomarkers in a sample. The biocompatible SERS-active polymer membrane includes a flexible and porous polymer membrane and SERS-active nanoparticles formed on the flexible and porous polymer membrane, where the flexible and porous polymer membrane includes cellulose or an elastomeric polymer. Also disclosed herein is a method of forming the biocompatible SERS-active polymer membrane and a method of determining a state of wound healing in a diabetic individual involving the use of the biocompatible SERS-active polymer membrane.

IPC Classes  ?

• G01N 21/65 - Raman scattering
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Described herein is a hydrogel comprising a peptide and gelatin. The peptide comprises a sequence having at least 8 amino acids with alternating hydrophobic amino acids (X) and hydrophilic amino acids (Y), wherein each hydrophobic amino acid is independently selected from isoleucine (I), valine (V) and leucine (L), each hydrophilic amino acid is independently selected from arginine (R), lysine (K), glutamic acid (E), and aspartic acid (D), wherein the hydrophilic amino acids are selected such that there is at least one arginine and at least one lysine. A kit and method for preparing the hydrogel is described as well. The hydrogel may be used to culture cells and determine an effect of a compound on a cell cultured in the hydrogel.

IPC Classes  ?

• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C12N 5/09 - Tumour cells

Abstract

There is provided an ion selective membrane comprising a polymer matrix and an ionic lipophilic additive covalently bonded to the polymer matrix. There are also provided a method of preparing the ion selective membrane, an ion selective electrode comprising the ion selective membrane and a method of preparing the ion selective electrode.

IPC Classes  ?

• C08J 5/22 - Films, membranes or diaphragms

Abstract

There is provided a method of producing a bioactive polymer filament, the method comprising: providing a base polymer powder and a bioactive copolymer; mixing the base polymer powder with the bioactive copolymer to obtain a mixture; and extruding a bioactive polymer filament from the mixture at an extrusion temperature profile that is based on a predetermined melt/softening temperature and a predetermined onset degradation temperature of the bioactive polymer; and performing a post-extrusion thermal analysis on the extended bioactive polymer filament to assess onset degradation of the bioactive copolymer in the filament. There is also provided a bioactive polymer filament obtained from said method and a fused filament fabrication (FFF) or fused deposition modelling (FDM) based three-dimensional printing method.

IPC Classes  ?

• B29C 48/05 - Filamentary, e.g. strands
• B29C 48/00 - Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired formApparatus therefor
• B29C 48/92 - Measuring, controlling or regulating
• B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
• B29K 67/00 - Use of polyesters as moulding material

Abstract

A photodetector and device thereof. The photodetector, operable by a source of a light, includes a first electrical contact, a second electrical contact, and a sensor layer. The sensor layer has a first end in contact with the first electrical contact and a second end in contact with the second electrical contact. The sensor layer includes a sensor surface. The sensor surface includes a first area corresponding to a first region of the sensor layer and a second area corresponding to a second region of the sensor layer, in which the first region and the second region are wholly formed of a similar active material, and in which the first area and the second area are differently configured from one another.

IPC Classes  ?

• H01L 31/0232 - Optical elements or arrangements associated with the device
• H01L 31/0236 - Special surface textures
• H10N 15/10 - Thermoelectric devices using thermal change of the dielectric constant, e.g. working above and below the Curie point
• H10N 19/00 - Integrated devices, or assemblies of multiple devices, comprising at least one thermoelectric or thermomagnetic element covered by groups

Abstract

We describe a Cnx/ERp57 inhibitor for use in the treatment or prevention of cancer.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The disclosure concerns bacterial cell counting devices, systems and methods thereof. The bacterial cell counting device comprises at least one cartridge for containing reagents; an inlet for introducing a sample containing bacterial cells into the device; an optofluidic chip separately in fluid communication with the cartridge and the inlet; a filter strip passing through the optofluidic chip and in fluid communication with the cartridge and the inlet, the filter strip for trapping or retaining bacterial cells on its surface such that the bacterial cells can interact with the reagents as they flow through the filter strip; and a controller for controlling a sequential flow of reagents and sample to the filter strip via the optofluidic chip. The optofluidic chip is capable of detecting a colorimetric and/or fluorescence output emitted from the bacterial cells modified by the reagents in order for the bacterial cells to be quantified relative to a control.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices

Abstract

The invention relates to a process and an apparatus for producing syngas and/or hydrocarbons. The process involves reacting ammonia and carbon dioxide in a single reactor in the presence of a transition metal catalyst to form one or more products comprising carbon monoxide, hydrogen and one or more hydrocarbons. The invention allows green ammonia as a liquefied hydrogen carrier to be used directly in CO2 conversion.

IPC Classes  ?

• C01B 3/02 - Production of hydrogen or of gaseous mixtures containing hydrogen
• C07C 1/02 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon
• B01J 8/02 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with stationary particles, e.g. in fixed beds
• B01J 23/74 - Iron group metals
• B01J 23/40 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of noble metals of the platinum group metals
• B01J 37/03 - PrecipitationCo-precipitation

Abstract

A stretchable conductive ink There is provided a stretchable conductive ink comprising: a carbon-based material; a conducting polymer; a viscoelastic polymer; and an amphiphilic polymer, wherein the conductive ink is hydrophilic. There is also provided an electrode for an electrochemical sensor comprising a substrate and the conductive ink.

IPC Classes  ?

• C09D 11/52 - Electrically conductive inks
• C09D 11/102 - Printing inks based on artificial resins containing macromolecular compounds obtained by reactions other than those only involving unsaturated carbon-to-carbon bonds
• H01M 4/96 - Carbon-based electrodes
• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01B 1/24 - Conductive material dispersed in non-conductive organic material the conductive material comprising carbon-silicon compounds, carbon, or silicon

Abstract

There is provided a method of detecting a population of macrophage in a sample comprising detecting and/or determining the expression of Cdh5 in the macrophage in the sample. Also disclosed is a kit for detecting and/or separating and/or depleting a population of a macrophage, a method of depleting a population of a macrophage, a method of improving the health of an obese and/or overweight subject, a method of determining the risk of obesity and/or a metabolic impairment related to obesity in a subject, and an animal model thereof.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

A portable device operable to identify photosynthetic activity and contents of compounds in a plant part. The portable device includes a light source including light-emitting diodes operable to irradiate the plant part with light. The portable device further includes a control module operable to have the light-emitting diodes emit the light as pulse signals. Additionally, the portable device includes a focus-adjustable lens and a filter optically coupled to the light source, where the adjustable lens and the filter are co-operable to consolidate light reflected from the plant part which may be irradiated by light from the light-emitting diodes. Furthermore, the portable device includes a detector optically positioned to receive from the focus-adjustable lens and the filter the light reflected from the plant part, where the light reflected from the plant part corresponds to the photosynthetic activity and contents of compounds in the plant part.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
• G01N 21/84 - Systems specially adapted for particular applications

Abstract

There is provided a method of removing gossypol from one or more plant parts, comprising incubating a mixture of the one or more plant parts with an acidified amino acid solution, wherein amino acid comprises more than one nitrogen-containing functionality. There is also provided a protein isolate having a total gossypol content of less than 250 ppm.

IPC Classes  ?

• A23J 1/14 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from leguminous or other vegetable seedsObtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from press-cake or oil-bearing seeds
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification

Abstract

There is provided a method of detecting and/or determining the presence of one or more thyroid-specific nucleic acid, the method comprising annealing the one or more thyroid-specific nucleic acid in the presence of a control nucleic acid, and subjecting each of the one or more thyroid-specific nucleic acid to one or more amplification step in the presence of a mixture comprising a surfactant and an oligonucleotide primer and/or probe capable of hybridizing with the one or more thyroid-specific nucleic acid, wherein the oligonucleotide primer and/or probe comprises a cleavage site and a cleavable 3′ end. Also disclosed are methods of detecting and/or determining thyroid cancer recurrence and/or metastasis and thyroid-specific nucleic acid detection mixtures, and kits thereof.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

There is provided herein a paper-based sensor for simultaneously determining a plurality of biomarkers present in a biological sample comprising a plurality of detection zones in fluid communication with a sampling zone, wherein said plurality of detection zones comprises sensing material specific to each of said plurality of biomarkers. There is also provided herein a method of manufacturing the paper-based sensor, a use of a paper-based sensor for wound diagnosis, a kit comprising the paper-based sensor and a method of diagnosing wound health.

IPC Classes  ?

• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH

Abstract

The invention relates to a method for decellularization of tissue samples to produce decellularized extracellular matrix (dECM) by performing one or more wash cycles in a reactor using a reagent after at least partially submerging the tissue sample in the reagent, wherein the reactor comprising a tissue chamber in fluid communication with a reactor chamber. The method further comprising the steps of agitating the tissue sample and/or the reagent such that the tissue sample circulates in the reagent while retaining the tissue sample in a tissue chamber or a decellularization reactor, monitoring at least one parameter of the reagent and/or at least one parameter of the tissue sample, and adjusting one or more wash cycles based on said monitoring. The invention further relates to a decellularization reactor and a decellularization system for decellularizing a tissue sample.

IPC Classes  ?

• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof

Abstract

This disclosure relates to a method of amplification of a target nucleic acid, the method comprising subjecting the target nucleic acid to one or more amplification step in the presence of a mixture comprising a control nuclei acid, a surfactant and an oligonucleotide primer and/or probe capable of hybridizing with the target nucleic acid, wherein the oligonucleotide primer and/or probe comprises a cleavage site and a cleavable 3′ end. In one embodiment, the target nucleic acid is cell-free RNA and the method comprises annealing the target nucleic acid and performing a reverse transcription prior to the one or more amplification step. Also disclosed are nucleic acid amplification mixtures, kits for amplifications, and methods of detecting and/or determining the presence and/or the amount of a target nucleic acid.

IPC Classes  ?

• C12Q 1/6851 - Quantitative amplification
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

The present invention relates to the use of a therapeutically effective amount of microRNA-101-3p (miR-101-3p) for treating a subject suffering from psoriasis via the modulation of expression of Enhancer of Zeste homolog 2 (EZH2).

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 17/06 - Antipsoriatics

Abstract

The present invention relates to polypeptides for degrading polyesters. Disclosed herein are microbially-derived polypeptides and engineered variants thereof for degrading polyethylene terephthalate (PET) and other polyesters. Also provided are methods of producing the polypeptides and methods for polyester degradation using the polypeptides.

IPC Classes  ?

• C12N 15/55 - Hydrolases (3)
• C12N 9/18 - Carboxylic ester hydrolases
• B09B 3/60 - Biochemical treatment, e.g. by using enzymes
• B09B 101/75 - Plastic waste

Abstract

This disclosure relates to a method of assessing/monitoring the health of a subject, the method comprising subjecting a pancreas-associated polynucleotide to one or more amplification step in the presence of a mixture comprising a control nuclei acid, a surfactant and an oligonucleotide primer and/or probe capable of hybridizing with the target nucleic acid, wherein the oligonucleotide primer and/or probe comprises a cleavage site and a cleavable 3′ end. In one embodiment, the pancreas-associated polynucleotide is cell-free RNA and the method comprises annealing the target nucleic acid and performing a reverse transcription prior to the one or more amplification step. Also disclosed are primer and/or primer sets as disclosed herein and kits for use thereof.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to isolated and engineered human antibodies that specifically bind to at least one conformational (non-linear) epitope of HBsAg and neutralize hepatitis B virus infection, methods for producing the same, and uses thereof in treating human HBV infection.

IPC Classes  ?

• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/20 - Antivirals for DNA viruses
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates to functionalised polypeptides, nanoparticles and their 5 uses thereof. The functionalised polypeptide comprises polylysine functionalised with guanidinium moieties, wherein the polypeptide is about 50% to about 98% functionalised. The number of guanidinium functionalised lysine monomeric units is 5 to 100, and the number of lysine monomeric units is 1 to 50. The functionalised polypeptides and nanoparticles can be used for treating a microbial infection or for 10 treating cancer.

IPC Classes  ?

• C07K 14/01 - DNA viruses
• A61K 9/14 - Particulate form, e.g. powders
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents

Abstract

This document describes a waveguide antenna array for use in an optical phased array (OPA) such that the OPA is able to achieve a wide field of view and grating-lobe-free far field projection. The waveguide antenna array comprises a first waveguide antenna having periodic perturbations comprising first waveguide sections and first perturbed sections, a second waveguide antenna having periodic perturbations comprising second waveguide sections and second perturbed sections. A pitch between the first and second waveguide antenna is equal or less than half an operating wavelength of an optical signal to be received by the waveguide antenna array. A width of the first waveguide section is different from a width of the second waveguide section. The perturbation period of the first waveguide antenna is different from the perturbation period of the second waveguide antenna.

IPC Classes  ?

• G02F 1/295 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the position or the direction of light beams, i.e. deflection in an optical waveguide structure
• G02B 6/122 - Basic optical elements, e.g. light-guiding paths
• G01S 7/481 - Constructional features, e.g. arrangements of optical elements
• H01Q 3/26 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the relative phase or relative amplitude of energisation between two or more active radiating elementsArrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture

Abstract

A method for fabricating an optic element is provided. The method may include: fabricating a first mold having a pattern of the optic element; fabricating a second mold with a soft material by using the first mold, the second mold having an opposite pattern to the pattern of the optic element; forming a nanocomposite layer on a substrate, wherein the nanocomposite layer comprises nanoparticles embedded therein, the nanocomposite layer having a refractive index which is equal to or greater than 2; placing the second mold onto the nanocomposite layer and curing the nanocomposite layer; demolding the cured nanocomposite layer from the second mold to obtain the optic element.

IPC Classes  ?

• G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements

Abstract

A method and an apparatus for generating one or more differentiated oral prompt for learning, the method comprising: presenting a learning task to a user on a display; receiving user feedback to the learning task; determining a diagnosis input based on the user feedback; performing a diagnosis, using a prompt generation model, on the diagnosis input to generate a differentiated oral prompt and a differentiated speech highlighting mask associated with the differentiated oral prompt, wherein the differentiated speech highlighting mask include data indicative of prosodic control; inputting the differentiated oral prompt and the differentiated speech highlighting mask to a Text-to-Speech module with prosody control to generate speech signals for reading out the differentiated oral prompt with speech highlights specified in the differentiated speech highlighting mask; and converting the speech signals into a format for reading out the differentiated oral prompt with the specified speech highlights through an audio device.

IPC Classes  ?

• G09B 5/06 - Electrically-operated educational appliances with both visual and audible presentation of the material to be studied
• G09B 5/08 - Electrically-operated educational appliances providing for individual presentation of information to a plurality of student stations
• G10L 13/10 - Prosody rules derived from textStress or intonation

Abstract

This disclosure provides a tunable laser which is capable of self-recalibrating its wavelength-voltage tuning table by performing wavelength-voltage tuning function initialisation without any additional measurement equipment. This is enabled by using a combination of etalon and photodetector. This disclosure also provides for improved wavelength reliability by performing wavelength-voltage tuning function initialisation and temperature-assisted initialisation until a desired wavelength reliability is obtained.

IPC Classes  ?

• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range
• H01S 5/00 - Semiconductor lasers

Abstract

A SERS substrate includes: a base, an array of nanostructures formed on the base, a first coating disposed on the array of nanostructures, and a second coating disposed on the first coating The first coating includes a thin film formed of a noble metal. The second coating includes a metallic/semimetallic two-dimensional material. The metallic/semimetallic two-dimensional material may include one or more transition metal dichalcogenides. A method of making a SERS substrate include: plasma etching a base to form an array of nanostructures on the base; forming a first coating on the array of nanostructures, the first coating being a thin film formed of a noble metal; and forming a second coating on the first coating. The method may further include: forming a plurality of two-dimensional flakes using electrochemical exfoliation; and depositing the plurality of two-dimensional flakes after the first coating is formed.

IPC Classes  ?

• G01N 21/65 - Raman scattering
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• B82Y 40/00 - Manufacture or treatment of nanostructures
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• C01G 35/00 - Compounds of tantalum

Abstract

There is provided a compound comprising a structure represented by general formula (1) or ionized forms thereof for preparing lipid nanoparticles encapsulating a cationic therapeutic and/or cationic prophylactic agent: wherein R1 and R2 are each independently a hydrophobic group; X comprises an optionally substituted linear aliphatic, optionally substituted branched aliphatic and/or optionally substituted cyclic hydrocarbons; and A comprises a peptide sequence of 1-5 anionic amino acids.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 31/04 - Antibacterial agents

Abstract

Method for feeding material into plasma for spheroidization There is provided a method for producing a spheroidized powder from a feed stream comprising metal powder, the method comprising feeding a first feed stream comprising metal powder into a plasma chamber at a first angle offset from plasma flow within the plasma chamber; and melting and spheroidizing the metal powder within the plasma chamber to form spheroidized powder, wherein the first angle offset from plasma flow is in a direction against the plasma flow. There is also provided a nozzle for feeding a feed stream into a plasma chamber.

IPC Classes  ?

• B22F 9/14 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using physical processes using electric discharge
• B22F 9/04 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using physical processes starting from solid material, e.g. by crushing, grinding or milling
• B29C 64/314 - Preparation
• B33Y 40/00 - Auxiliary operations or equipment, e.g. for material handling
• B05B 1/34 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
• B22F 1/065 - Spherical particles

Abstract

Disclosed herein is a lifting device, a lifting system and a method of lifting a load. The lifting device comprises a frame couplable to a support; a plurality of wire rope systems coupled to the frame, the plurality of wire rope systems being configured to hold a load relative to the frame, wherein each of the plurality of wire rope systems comprises a wire rope with an independently adjustable operating length; and a plurality of sensors coupled to the frame, the plurality of sensors being configured to sense at least one parameter of the load.

IPC Classes  ?

• B66C 1/16 - Slings with load-engaging platforms or frameworks
• B66C 13/06 - Auxiliary devices for controlling movements of suspended loads, or for preventing cable slack for minimising or preventing longitudinal or transverse swinging of loads
• B66C 13/08 - Auxiliary devices for controlling movements of suspended loads, or for preventing cable slack for depositing loads in desired attitudes or positions
• B66C 13/46 - Position indicators for suspended loads or for crane elements

Abstract

A sensor substrate includes: a base of silicon; and a plurality of bars. Each of the plurality of bars may be formed of at least a first noble metal. The plurality of bars may be disposed on a first area of the base in an array of units. Each of the units may include: at least one long bar; and at least one short bar. The short bar is shorter in length than the long bar. The array may be a periodic array characterized by a surface enhanced infrared absorption (SEIRA) resonance in an infrared (IR) spectrum. Each of the plurality of bars may include at least one interface characterized by a surface enhanced Raman spectroscopy (SERS) resonance.

IPC Classes  ?

• G01N 21/65 - Raman scattering
• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• B82Y 40/00 - Manufacture or treatment of nanostructures
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals

Abstract

Various embodiments may relate to a liquid crystal (LC) device. The liquid crystal (LC) device may include a first electrode. The liquid crystal (LC) device may also include a second electrode. The liquid crystal (LC) device may further include a liquid crystal layer between the first electrode and the second electrode, the liquid crystal layer including liquid crystal molecules and an array of nanostructures adapted to cause a desired alignment of the liquid crystal molecules and to modulate light passing through the liquid crystal device. A periodicity of the array of nanostructures or an aspect ratio of each nanostructure of the array of nanostructures may be adapted to cause the desired alignment of the liquid crystal molecules.

IPC Classes  ?

• G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements
• G02F 1/1335 - Structural association of cells with optical devices, e.g. polarisers or reflectors
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals

Abstract

A device and method of monitoring a surface defect on a proximal wall of a structure includes transmitting a generated ultrasonic bulk wave from an ultrasonic transducer array disposed on the proximal wall, the generated ultrasonic bulk wave being transmitted from the proximal wall as a spread wave having a central line angularly displaced relative to the proximal wall. The method includes determining at least one characteristic of the surface defect based on a reflected ultrasonic bulk wave sensed by the ultrasonic transducer array, the ultrasonic transducer array being disposed on the proximal wall and disposed to one side of the surface defect. The method may include determining at least one characteristic of the surface defect based on respective arrival times of the reflected ultrasonic bulk wave sensed by at least two ultrasonic transducers selected from the ultrasonic transducer array.

IPC Classes  ?

• G01N 29/24 - Probes
• G01N 29/22 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details
• G01N 29/04 - Analysing solids
• G01N 29/07 - Analysing solids by measuring propagation velocity or propagation time of acoustic waves

Abstract

Disclosed herein are compositions comprising at least one modified adeno-associated viral (AAV) capsid protein. Also disclosed herein are adeno-associated virus particles comprising the AAV capsid proteins disclosed herein. In one example, the compositions, nucleic acids, vectors, host cells and adeno- associated virus particles disclosed herein are used in therapy.

IPC Classes  ?

• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 15/86 - Viral vectors
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 35/76 - VirusesSubviral particlesBacteriophages

Abstract

Disclosed herein are methods of identifying a gastric cancer stem cell or gastric cancer stem cell population. Also described herein are methods of isolating one or more gastric cancer stem cells from a cell population, comprising contacting cells of the cell population with an agent that binds to AQP5, isolating one or more AQP5-expressing cells that are bound to the agent, wherein the one or more AQP5-expressing cells are gastric cancer stem cells. Further described herein are methods of ablating or eliminating an AQP5+ gastric cancer stem cells, as well as methods of treating gastric cancer, and methods of monitoring gastric cancer tumorigenesis or progression of gastric cancer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure generally relates to a flow reactor system (100) and a flow reaction method (200). The flow reactor system (100) comprises liquid pumps (110) for communicating liquid reagents based on a set of flow conditions, a fluid pump (200) for communicating a carrier fluid that is immiscible with the liquid reagents; a fluidic mixer (130) for mixing the liquid reagents into a liquid mixture, a measurement device (150) for measuring properties of liquid plugs (140) discharged from an outlet (136) of the fluidic mixer (130); and a control module configured for controlling the liquid pumps (110) and adjusting the flow conditions based on the measured properties of the liquid plugs (140), wherein the liquid plugs (140) are representative of different flow conditions.

IPC Classes  ?

• B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
• B01J 4/00 - Feed devicesFeed or outlet control devices
• B01J 14/00 - Chemical processes in general for reacting liquids with liquidsApparatus specially adapted therefor
• B01J 19/24 - Stationary reactors without moving elements inside
• B29C 64/314 - Preparation
• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 40/00 - Auxiliary operations or equipment, e.g. for material handling
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes

Abstract

This technology relates to a method of isolating adipose-derived cell lines from an animal, a method of isolating adipocytes from an animal, and isolated adipose-derived cell lines thereof.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells